

Drug Monograph

Drug/Drug **Lexette® (halobetasol propionate) 0.05% topical foam/**
 Class: **Topical Corticosteroids**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Lexette® 0.05% topical foam is available in a 50g container.

Manufacturer: MAYNE PHARMA LLC, Greenville, NC 27834

Indications: Lexette® topical foam is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

Costs: \$770.50 per 50g container of Lexette® Topical Foam. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Non-Preferred
 Appropriate Indications No PA Required

Prepared By: Jennifer Anderson PharmD
 Date: January 27, 2019